BOSTON SCIENTIFIC CORP Form 8-K July 07, 2005

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

## Washington, DC 20549

## FORM 8-K

## **CURRENT REPORT**

## PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 1, 2005

## **BOSTON SCIENTIFIC CORPORATION**

(Exact name of registrant as specified in charter)

**DELAWARE** (State or other jurisdiction of incorporation) <u>1-11083</u> (Commission file number) 04-2695240 (IRS employer identification no.)

## <u>One Boston Scientific Place, Natick, Massachusetts</u> (Address of principal executive offices)

01760-1537 (Zip code)

Registrant s telephone number, including area code: (508) 650-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the fling obligation of the registrant under any of the following provisions:

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### ITEM 8.01. OTHER EVENTS.

On July 1, 2005, a jury in the United States District Court in Delaware found that Johnson & Johnson s CYPHER drug-eluting stent infringes one of our patents related to polymer coatings, and that Johnson & Johnson s CYPHER, Bx VELOCITY, Bx SONIC and GENESIS stents infringe another patent covering stent design. The jury also upheld the validity of both patents. A hearing to determine damages and any other relief will be held at a later date.

### ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

99.1 Press Release dated July 1, 2005

## SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## BOSTON SCIENTIFIC CORPORATION

Date: July 7, 2005

By: /s/ Lawrence J. Knopf

Lawrence J. Knopf Vice President and Assistant General Counsel

## INDEX TO EXHIBITS

# <u>EXHIBIT</u>

# NUMBER DESCRIPTION

99.1 Press Release dated July 1, 2005